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Abstract: Herpes simplex keratitis (HSK) is a major cause of corneal blindness in the world. Following the primary infection, the virus 
enters into a latent phase. Recurrent infectious or immune keratitis cause structural damage to the cornea, scarring, and may lead to 
blindness. Several commercially available topical and oral antiviral drugs for HSK are currently available. However, toxicity and low 
patient compliance hamper their use in HSK. Further, oral antiviral drugs alone are not always effective in HSK. Thus, there had been a 
need for safe and effective topical antiviral agents against HSK. Systemic ganciclovir has been in use for the treatment of cytomegalo-
virus infections. Recently, topical ganciclovir has become available for use in patients with HSK. Ganciclovir 0.15% ophthalmic gel has 
been shown to be both safe and effective against viruses of the herpes family. Topical ganciclovir ophthalmic gel is well tolerated and 
does not cause significant toxic effects on the ocular surface. Several multicenter studies have revealed the potential role of ganciclovir 
ophthalmic gel in the treatment and prophylaxis of epithelial HSK. In this paper, we have reviewed the pharmacology, efficacy, side 
effects, and the role of ganciclovir ophthalmic gel 0.15% in the treatment of acute herpetic keratitis.
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Introduction
The herpes simplex virus type 1 (HSV-1) and type 2 
(HSV-2) belong to family of herpes viridae, including 
varicella-zoster, Epstein-Barr, cytomegalovirus, and 
human herpes viruses types 6–8.1,2 While ocular dis-
ease is typically caused by HSV-1, and HSV-2 infec-
tions generally affect the genital area, this division 
is  not  mutually  exclusive.  Following  the  primary 
infection with HSV-1, the virus undergoes a charac-
teristic non-replicating latent state in the trigeminal 
ganglion.3,4 Although the primary infection may be 
asymptomatic, it can also have a severe presentation, 
particularly in children and newborns, with involve-
ment of the central nervous system in the form of 
encephalitis or meningitis.1,4
HSV keratitis (HSK) is the most common infec-
tious cause of unilateral blindness in the developed 
world.5–7 In the United States alone, the total number 
of episodes is estimated to be around 48,000 per year, 
with approximately 20,000 new cases per year.8–10 In 
contrast, congenital ocular herpetic disease is rather 
rare,  with  HSV-2  accounting  for  80%  of    cases.1 
  Primary ocular HSV presents as periocular and eyelid 
vesicles, acute follicular conjunctivitis, and in some 
cases with keratoconjunctivitis (Fig. 1).5 While latent 
in the trigeminal ganglion, HSV can reactivate any-
time during lifetime, particularly by stress, UV radia-
tion, a compromised immune system, and hormonal 
changes.1,2,5,7–12 Though recurrent disease may affect 
any ocular tissue, it is more common in the cornea 
and uvea. Recurrent HSK can ultimately lead to cor-
neal  scarring,  ocular  surface  disease,  neurotrophic 
keratopathy, and consequently to corneal perforation 
and blindness in severe cases1,2 (Fig. 2). Therefore 
prompt treatment is extremely important in the man-
agement of ocular HSV disease.
In the past two decades, management of ocular 
HSV  infection  has  improved  considerably  due  to 
advances  in  topical  and  systemic  antiviral  drugs. 
Treatment of HSK is tailored to patients depending 
on the clinical manifestation, the affected layer, and 
severity  of    disease.  Epithelial  forms  are  generally 
treated with oral and/or topical antiviral therapy. Until 
recently, five topical ophthalmic antiviral drugs have 
been available in the United States and Europe: idox-
uridine (IDU), iododesoxycytidine, vidarabine, triflu-
ridine 1% (Viroptic), and acyclovir 3%   (Zovirax®). 
  However, toxicity of these topical antiviral drugs and 
their  poor  tolerance  have  remained  a  major  prob-
lem.13,14 More recently, ganciclovir has become avail-
able as an 0.15% ophthalmic gel (Zirgan™).
Idoxuridine  was  the  first  antiviral  used  to  treat 
HSV-1  infections;  however,  side  effects  and  poor 
aqueous solubility limited its topical use. Vidarabine, 
also developed for the treatment of HSK, had fewer 
toxic side effects than IDU, but had poor solubility. 
Currently, trifluridine ophthalmic solution (Viroptic) 
is the most widely used topical antiviral drug for the 
treatment of epithelial HSK in the United States (US). 
TFT, a nucleoside analogue, is activated by viral and 
host cell thymidine kinase and is integrated into the 
DNA of both the herpes virus and host cells.15–17 TFT 
should not be used longer than 3 weeks by patients, 
due to its severe ocular toxicity. Moreover, because 
of its low solubility, the corneal penetration is limited 
when the corneal epithelium is intact.13,14,18–25
Acyclovir  and  the  more  recent  addition  to  the 
armamentarium against HSV, ganciclovir, both tar-
get only infected cells and are therefore less toxic 
then  their  previous  counterparts.26,27  They  inhibit 
viral replication in a similar manner as trifluridine. 
  However, thymidine kinase phosphorylates acyclovir 
Figure 1. (A) Dendritic corneal lesion caused by herpes simplex virus. (B) After topical fluorescein drop installation the same lesion shows hyperfluores-
cence under cobalt blue light.Ganciclovir gel in acute herpetic keratitis
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and   ganciclovir primarily in infected cells.16,17 After 
phosphorylation, they inhibit viral DNA polymerase 
and/or directly incorporate into the viral primer strand 
DNA.28–32 Acyclovir has poor aqueous solubility and 
is thus formulated as an ointment. Although acyclo-
vir is highly effective against HSK, patient compli-
ance is severely hindered due to blurring of vision 
after application of the ointment. Moreover, acyclovir 
ophthalmic ointment is not commercially available in 
the United States. Ganciclovir, which has a similar 
activity as acyclovir, has previously been widely used 
via both oral and intravenous routes.33–40 Ganciclovir 
has a wide-spectrum against HSV-1, HSV-2, Epstein-
Barr virus, varicella zoster virus, cytomegalovirus, 
human herpes viruses, and adenoviruses.35,36,40–42 In 
contrast to acyclovir, however, ganciclovir has good 
water solubility, allowing for preparation of its gel 
form. Although  ganciclovir  ophthalmic  gel  0.15% 
(Zirgan™)  was  approved  for  topical  use  in  some 
European countries as Virgan since 1995, it was only 
just recently approved in the United States for acute 
herpetic keratitis in September 2009.31,43
Herein, we will review the pharmacology, efficacy, 
side effects, and role of ganciclovir ophthalmic gel 
0.15% in the treatment of acute herpetic keratitis.
Mechanism of Action, Metabolism, 
and Pharmacokinetic Profile
Ganciclovir  is  a  synthetic  nucleoside  analogue  of 
2′-deoxyguanosine  and  has  a  molecular  weight  of 
255.23.28,43 The chemical name is 9-[[2-hydroxy-1-
(hydroxymethyl)ethoxy]methyl]guanine (CAS num-
ber 82410-32-0).28,43 It is selectively phosphorylated 
by viral thymidine kinase of the herpes viruses and 
by  protein  kinase  of  CMV.29,40,44  This  phosphory-
lated  form  is  further  phosphorylated  by  both  viral 
and    cellular  thymidine  kinases  of  virus  infected 
cells.44  The  ultimate  product,  ganciclovir  triphos-
phate, is the active metabolite and accumulates only 
in infected host cells avoiding toxicity to the unin-
fected healthy cells. It has an intracellular half-life 
more than 24 hours. The active metabolite inhibits 
viral DNA synthesis by competitively binding to DNA 
  polymerase. Further, it works through direct incorpo-
ration of the active metabolite into viral strand primer 
DNA, which results in chain termination and inhibi-
tion of viral replication.43
Although it is structurally and pharmacologically 
similar to acyclovir, ganciclovir has a lower antivi-
ral  activity  against  cytomegalovirus  (CMV)  and  a 
lower selectivity for viral DNA.40 Oral, intravenous 
(IV),  intravitreal,  and  topical  forms  are  available. 
Parenteral ganciclovir is being used for induction and 
maintenance therapy against CMV retinitis in patients 
with acquired immune deficiency syndrome (AIDS).45 
Oral ganciclovir has been approved for maintenance 
therapy against CMV retinitis in patients whose active 
retinitis was resolved by IV induction therapy.46 Oral 
ganciclovir is also approved in patients with advanced 
human immunodeficiency virus (HIV) infection for the 
prophylaxis against CMV retinitis.46 Oral ganciclovir 
is poorly absorbed from the gastrointestinal tract.47 
The absolute bioavailability of oral ganciclovir under 
fasting conditions is about 5%, and about 6% to 9% 
when administered with food.47 Thus, subsequently, 
the ganciclovir intravitreal implant   (Vitrasert®) was 
developed and approved by the FDA in March 1996, 
for intraocular treatment of CMV retinitis in patients 
with AIDS.48
Systemic  ganciclovir  is  widely  distributed 
to  all  tissues  and  crosses  the  placenta,  without 
marked  accumulation  in  any  one  type  of  tissue.47,49 
Figure 2. (A) Geographic ulcer showing hyperfluorescence on a corneal graft. (B) High magnification photo of the same lesion. 
note: Terminal bulbs, which are characteristic of herpetic epithelial keratitis, are present.Sahin and Hamrah
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In addition,   systemic   ganciclovir has a good intraocu-
lar   distribution.   Following IV administration,   subretinal 
concentrations  reach  between  0.87  to  2-fold  higher 
concentrations  than  the  plasma  at  5.5  and  8  hours, 
  respectively.49  Concentrations  of    ganciclovir  in  the 
aqueous  humor  and  the  vitreous  body  have  been 
reported  to  be  0.4  and  0.6  higher,  than  concurrent 
plasma  concentrations  at  2.5  hours  following  IV 
administration.49
Ganciclovir has a similar antiviral activity to acy-
clovir against HSV-1 and HSV-2.38,40 Although it has 
lower antiviral activity against CMV when compared 
to that of acyclovir, intracellular concentrations of its 
active metabolite are higher.40 In vitro, the mean effec-
tive dose of ganciclovir against HSV-1 and HSV-2 is 
0.23 µg/mL.41,50,51 Several studies have reported on 
the required ganciclovir concentrations necessary to 
achieve 50% inhibition of viral activity (ID50). The 
range for treatment against HSV-1 has been reported 
to be 0.2–2.0 µmol/L, while for HSV-2 this range has 
been reported to be 0.3–10.0 µmol/L.29,38 In contrast, 
the 50% inhibitory concentrations (IC50) for CMV is 
10.0 µmol/L, 8.0 µmol/L for VZV, and 1.0 µmol/L 
for EBV.44 Further, ganciclovir has a ID50 value of 
26–47 µmol/L for adenoviruses.44
The  pharmacokinetics  and  efficacy  of  ganciclo-
vir ophthalmic gel have been evaluated in preclini-
cal  studies.  In  an  experimental  model  of  HSK  in 
rabbits,52  0.1%  ganciclovir  ointment  demonstrated 
antiviral activity. Castela et al53 used ganciclovir oph-
thalmic gel in the same model, where the gel was 
prepared in Carbomer 934P (NF XVII, Transphyto 
SA,   Clermont-Ferrand, France) at concentrations of 
0.0125%, 0.05%, and 0.2%. The efficacy was com-
pared  against  placebo  and  3%  acyclovir  ophthal-
mic ointment. Both acyclovir and ganciclovir were 
found to reach higher levels in the cornea than in the 
aqueous humor. This higher penetration in the cor-
nea was attributed to the small size of ganciclovir 
molecule, its high lipophilicity, and its high cellular 
affinity  stemming  from  its  endogenous  structural 
  nucleosides. All three ganciclovir gel concentrations 
effectively  treated  herpetic  keratitis,  without  any 
reported ocular   toxicity. In the same study by Castela 
et al,53   ganciclovir was detected in the aqueous humor 
of healthy rabbits even four hours after the last topical 
administration of a 2% concentration. The fact that 
ganciclovir is retained and detected in the aqueous 
humor for a prolonged period of time after the last 
topical administration, might be attributed to the slow 
diffusion of the drug through the cornea.
Although  the  ocular  distribution  and  tissue 
  concentration of ganciclovir ophthalmic gel 0.15% 
are  similar  to  acyclovir  3%  ointment,  its  systemic 
absorption  is  very  low.54  This  shows  the  limited 
plasma diffusion of the drug and its lack of system-
atic  toxicity.31  Pharmacokinetics  studies  of  topical 
ganciclovir in 6 healthy volunteers,55,56 receiving gan-
ciclovir 0.15% ophthalmic gel into each eye in 3-hour 
intervals for 12 hours demonstrated a mean concen-
tration of ganciclovir in tears ranging from 0.92 to 
6.86 µg/mL and no ocular discomfort. This concen-
tration is higher than the inhibitory concentrations for 
HSV-1. The wide range of intra- and inter-individual 
variations noted in the tears was attributed to reflex 
tearing during tear collection.
Topical drugs require an ideal balance between sol-
ubility and lipophilicity, in order to penetrate deeper 
into tissues. As such, highly lipophilic compounds 
are not able to penetrate the lipoidal corneal epithe-
lial layer. Thus, due to the relatively hydrophilicity 
of ganciclovir, its tissue permeation is limited and it 
passes the cornea primarily by passive diffusion.57,58 
Moreover, tight junctions between corneal epithelial 
cells  limit  paracellular  diffusion,  requiring  a  high 
concentration gradient across the corneal epithelium 
in  order  to  achieve  therapeutic  concentrations  in 
deeper corneal layers. Although lipophilic ganciclo-
vir prodrugs have been developed using acid esters, 
poor aqueous solubility of these prodrugs has ham-
pered their usage as topical or intravitreal agents.59,60 
The features and properties of ganciclovir ophthalmic 
gel and acyclovir ophthalmic ointment are shown in 
Table 1.
The first antiviral agent idoxuridine suffered the 
same problem since poor aqueous solubility limited 
its topical use.61 Another drug, vidarabine, had fewer 
toxic effects, however it was also poorly soluble. 
  Previous studies showed that the more lipophilic-
ity, the lower solubility.59,60 Majumdar et al62 reported 
that the divaline acyclovir ester prodrug has greater 
solubility and corneal permeability relative to acy-
clovir.63 Based on this data, the authors evaluated 
permeability of   Val-ganciclovir, Val-val-ganciclovir, 
Tyr-Val-  ganciclovir, and Val-Tyr-ganciclovir.62 They 
demonstrated seven- to eight-fold greater transcorneal Ganciclovir gel in acute herpetic keratitis
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permeability of Val-ganciclovir and Val-Val-ganciclovir   
as  compared  to  ganciclovir.62  Further,  their  in  vivo 
studies  in  a  rabbit  HSK  model  showed  that  1%   
Val-val-ganciclovir was more effective than 1% tri-
flurotimidine in controlling epithelial HSV keratitis, 
suggesting Val-val-ganciclovir as an ideal candidate for   
topical ophthalmic application in the treatment of HSK.
clinical Trials
The  safety  and  tolerability  of  topical  ganciclovir 
0.15%  ophthalmic  gel  in  acute  herpetic  keratitis 
setting has been evaluated in two separate phase I 
trials,56,64 and four randomized, multinational, single-
masked, phase IIb or open-label, phase III compara-
tive clinical trials.54,55,65–70 These studies are reported 
in the US FDA drug approval review.71
Three of these four multicenter trials were phase IIb 
trials conducted in Africa (study 1), Europe (study 2), 
and Pakistan (study 3). A fourth study was a phase III 
trial that stratified patients by dendritic or geographic 
ulcers (study 4) and was carried out in four European 
and African centers. The inclusion criteria were simi-
lar for all trials. Immunocompetent patients with a 
  clinical diagnosis of dendritic or geographic ulcers 
without a virological confirmation were included in 
these  studies.28,29,54,65,72  Exclusion  criteria  included 
antiviral treatment during the previous 14 days, severe 
stromal keratitis, keratouveitis, previous corneal trans-
plantation (in the affected eye), a secondary bacterial 
infection of the cornea or conjunctiva, recent ocular 
trauma, visual acuity , 20/100 in the unaffected eye, 
or known sensitivity to treatment.28,29,54,65,72
The patients were randomized to separate groups 
either receiving five daily drops of ganciclovir ophthal-
mic gel or five applications of acyclovir 3% ointment. 
Double masking was impossible, as ganciclovir is an 
aqueous gel, while acyclovir is an ointment. All patients 
were treated until the ulcers were completely healed. In 
studies 1 and 3, patients were randomized to one of two 
ganciclovir strengths: 0.15% or 0.05%. Maximum treat-
ment duration was established at 21 days for dendritic 
lesions and 35 days for geographic ulcers (Table 2).
Safety
In a randomized double-masked phase I clinical trial, 
ganciclovir ophthalmic gel 0.15% was   administered 
Table 1. Features and properties of ganciclovir ophthalmic gel and acyclovir ophthalmic ointment.
Ganciclovir 0.15%67–70,† Acyclovir 3%67–70,* Trifluridine 1%14,18,20
Chemical name 9-[[2-hydroxy-1-(hydroxymethyl) 
ethoxy]methyl]guanine
9-((2-hydroxyethoxy)methyl) 
guanine
α,α,α -trifluorothymidine
indication† Treatment of Herpes  
simplex keratitis
Treatment of Herpes  
simplex keratitis
Treatment of Herpes 
simplex keratitis
Dosage and  
Administration
One drop in the affected  
eye(s) five times a day
1 cm ribbon of ointment,  
inside the lower conjunctival 
sac five times a day
One drop of solution onto 
the cornea of the affected 
eye every 2 hours while 
awake for a maximum 
daily dosage of nine drops
Contraindication None Patients with known  
hypersensitivity to  
acyclovir or valacyclovir
Patients who develop 
hypersensitivity reactions 
or chemical intolerance to 
trifluridine
Use in pregnancy Category C Category B3 Category C
Use in lactation Not known Does pass into 
breast milk
Should not be prescribed 
for nursing mothers unless 
the potential benefits 
outweigh the potential 
risks
Adverse events Blurred vision, eye irritation,  
punctate keratitis, and  
conjunctival hyperemia
Transient mild stinging,  
superficial punctate  
keratopathy, mild  
hyperemia
Mild, transient burning or 
stinging upon instillation, 
palpebral edema, 
superficial punctate 
keratopathy
notes: *Not available in United States. Available in Europe and other countries. †approved for epithelial dendritic keratitis in the United States and for 
herpetic keratitis in Europe.Sahin and Hamrah
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to one eye and the vehicle gel was administered to 
the other in 10 healthy volunteers. Both were applied 
5 times daily for 7 days.64 Before treatment, on the sec-
ond and seventh day of treatment, subjective measures 
and  ophthalmologic  examination  were    performed. 
Overall,  tolerance  was  good  and  no  changes  were 
observed  in  the  physical  examination  between  the 
visits. In a separate phase I trial, six healthy male 
volunteers instilled one dose of ganciclovir 0.15% 
ophthalmic gel into each eye at 3-hour intervals for 
12 hours (total of 4 instillations).56   Systemic absorp-
tion of ganciclovir ophthalmic gel 0.15% was found 
to be minimal with the total daily topical dose approx-
imately  0.04%  and  0.1%  of  the  oral  dose  and  IV 
doses, respectively, thus minimal systemic exposure 
is expected. Ganciclovir is designated by the FDA 
as pregnancy Category C and no controlled studies 
have been performed in pregnant women. Further, no 
data is available on possible secretion of ganciclovir 
in human milk. However, studies in rabbits and mice 
have shown that ganciclovir is both teratogenic and 
embryotoxic. Moreover, ganciclovir has been detected 
in the milk of laboratory animals, causing significant 
adverse effects in their offspring.
In  the  first  clinical  trial  in  patients  with  herpes 
simples  keratitis,  performed  between  April  1990–
May 1992, 67 eyes of 66 patients were treated with 
0.15% (23 eyes), 0.05% (22 eyes) ganciclovir oph-
thalmic gel or 3% acyclovir ointment (22 eyes) five 
times daily.67 The withdrawal rates due to poor toler-
ance were 13% in the 0.15% ganciclovir gel group, 
27.3% in the 0.05% ganciclovir gel group, and 31.8% 
in  the  3%  acyclovir  ointment  group. These  differ-
ences were not statistically significant. Stinging and 
burning was reported in 10 out of 22 patients receiv-
ing 3% acyclovir ointment, but only reported in 4 and 
5  patients  receiving  0.15%  and  0.05%  ganciclovir 
gel,   respectively. Blurred vision and toxic superficial 
punctate keratitis did were not statistically significant 
between the treatment groups.
In the second trial, performed between   December 
1990–May 1992, 37 patients were divided to receive 
either 0.15% ganciclovir gel or 3% acyclovir oint-
ment.54,55,68 More than 75% of the patients receiving 
acyclovir  experienced  blurred  vision,  as  compared 
to  less  then  40%  in  patients  receiving  ganciclovir 
gel. Acyclovir caused burning and stinging in more 
than 50% of patients, whereas only 16.7% of patients Ganciclovir gel in acute herpetic keratitis
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experienced these symptoms in the ganciclovir group. 
During the trial, investigators and study subjects were 
also asked to assess the tolerance of the drugs. All 
patients and investigators rated ganciclovir as excel-
lent, while only 67% of the patients and 75% of the 
investigators rated acyclovir excellent.
In the third trial, performed between May 1991–   
October 1992, 109 patients were included.54,55,69 Patients 
were  divided  into  three  groups:  36  patients  were   
treated with ganciclovir 0.15% gel, 35 patients were 
treated with ganciclovir 0.05% gel, and 38 patients   
were treated with acyclovir 3% ointment. The toler-
ability was satisfactory for all 3 treatment groups. One 
subject in the ganciclovir 0.15% group, 5 subjects in the 
ganciclovir 0.05% group, and 3 subjects in the acyclovir 
3%  group  reported  stinging  and  burning. Although 
lower concentration of ganciclovir caused more sting-
ing and burning, the difference was not statistically 
significant. The number of superficial punctate keratitis 
cases that appeared or were exacerbated while receiving 
treatment was similar throughout all treatment groups.   
No hematological side effects were observed.
In the fourth and largest multicenter clinical trial, 
performed between September 1992–September 1994, 
164 patients were enrolled at 28 study centers.54,55,70,72 
Patients  were  given  either  ganciclovir  0.15%  gel 
(n = 84) or acyclovir 3% ointment (n = 80) 5 times 
daily. Subjects in the ganciclovir 0.15% group toler-
ated the drug better than those in the acyclovir 3% 
group. Fewer patients (28.1%–45.7% of patients, range 
across visits through day 14) in the ganciclovir group 
reported blurring when compared to patients in the 
acyclovir group (50.9%–63.6% of patients, range across 
visits through day 14) at all time points (P , 0.02 at all 
time points except day 10 where P = 0.056).   Average 
duration of blurring was significantly shorter in gan-
ciclovir 0.15% group (164–301 seconds, range across 
visits through day 14) when compared to that of acy-
clovir 3% group (474–972 seconds, range across visits 
through day 14) at all time points, except for Day 14 for 
the ganciclovir 0.15% group. Fewer subjects report-
ing stinging or burning sensation in the ganciclovir 
0.15% group (P = 0.03) at Day 14. However, dura-
tion of stinging and burning was not statistically sig-
nificant between groups. In addition, the frequency 
of toxic superficial punctate keratitis was reduced by 
half in the ganciclovir 0.15% group as compared with 
the acyclovir group (P = 0.03 at day 10).   Further, the 
number  of    investigators,  who  considered  ganciclo-
vir as excellent based on a questionnaire, were sig-
nificantly higher when compared with the acyclovir 
group  (P  =  0.00006  at  all  time  points  combined). 
Similarly, patients reported that the overall tolerability 
with ganciclovir 0.15% was more frequently consid-
ered excellent compared with acyclovir (P = 0.0002 
at all time points combined). Taken together, ganci-
clovir  exhibited  lower  rates  of  visual  disturbances 
and  toxic  superficial  punctate  keratopathy  (SPK). 
Moreover, ganciclovir caused less stinging/burning. 
Finally, the percentage of patients and investigators 
rating tolerability as excellent was significantly higher 
for ganciclovir.55,70
Efficacy
The  efficacy  of  topical  ganciclovir  ophthalmic  gel 
0.15% in the treatment of acute herpetic keratitis has 
been evaluated in preclinical animal models and in 
prospective randomized clinical trials.28,52–54,72,73
Study i
Patients were treated with ganciclovir 0.15%, ganci-
clovir 0.05%, or acyclovir 3% 5 times daily until heal-
ing of the ulcer and then 3 times daily for 1 week. 
Twenty-three  eyes  received  ganciclovir  0.15%, 
22 eyes received acyclovir 3% ointment, and 22 eyes 
received ganciclovir 0.05%. All eyes were included in 
the intention-to-treat (ITT) analysis. The per protocol 
(PP) analysis included 59 eyes (20 in the ganciclovir 
0.15% group, 18 in the acyclovir group, and 21 in the 
ganciclovir 0.05% group). The healing rate (in the ITT 
analysis) was 82.6% for the ganciclovir 0.15% group, 
77.3% for the ganciclovir 0.05% group, and 72.7% 
for the acyclovir group. The median healing time was 
7 days in the ganciclovir 0.15% and ganciclovir 0.05% 
groups and 8 days in the acyclovir group. The number 
of relapses was 1 in the ganciclovir 0.15% and ganci-
clovir 0.05% groups and 3 in the acyclovir group. In 
the ITT analyses, a tendency emerged in favor of gan-
ciclovir 0.15% in comparison with ganciclovir 0.05% 
and a slightly greater efficacy of ganciclovir 0.05% 
compared with acyclovir 3%.29,31,55
Study ii
This study was conducted at 4 study centers located 
in  France  (Brest,  Clermont-Ferrand),  Switzerland 
(Lausanne), and the United Kingdom (Bristol) from Sahin and Hamrah
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December 1990 through May 1992.55,68 Thirty seven 
patients enrolled in this study in which 19 patients were 
treated with ganciclovir 0.15% gel and 18 patients 
were treated with acyclovir 3% ophthalmic ointment. 
Patients  were  given  either  ganciclovir  or  acyclo-
vir 5 times daily until healing of the ulcer and then 
3 times daily for 1 week. It was found that ganciclo-
vir 0.15% was at least as effective as acyclovir 3% 
in healing the ulcers. Healing rate was 83.3% in the 
ganciclovir 0.15% group and 70.6% in the acyclovir 
3% group at day 14. The median time of healing was 
6 and 7 days for ganciclovir 0.15% and 7 acyclovir 
3%, respectively. There were no recurrences for gan-
ciclovir 0.15% and 1 for acyclovir 3%. While only 
35 patients were included in the efficacy analysis, all 
37 patients receiving the test agents were included in 
the tolerance analysis.29,31,55
Study iii
One hundred and nine patients were enrolled in this 
study. It was conducted from May 1991 to October 
1992 at one study center in Karachi, Pakistan, gan-
ciclovir 0.15% was found to be at least as effective 
as acyclovir 3%.55,69 Thirty six patients were treated 
with  ganciclovir  0.15%,  35  patients  were  treated 
with ganciclovir 0.05%, and 38 patients were treated 
with acyclovir 3%. In the ITT population, the heal-
ing rate was 86.1% with ganciclovir 0.15%, 80.0% 
with ganciclovir 0.05%, and 71.05% with acyclovir 
3%. The median time to healing was 7 days with 
acyclovir, 6 days with ganciclovir 0.15%, and 4 days 
with ganciclovir 0.05%. There were 3 relapses with 
acyclovir,  compared  to  0  with  ganciclovir  0.15% 
and 2 with ganciclovir 0.05%. Additionally, 21.05% 
of acyclovir patients, 11.4% of ganciclovir 0.05% 
patients,  and  5.6%  of  ganciclovir  0.15%  patients 
withdrew from the study due to worsening of the 
ulcer.29,31,55
Study iv
This  study  included  164  patients  at  28  European 
  centers.  It  was  conducted  from  September  1992 
through September 1994. The study centers were in 
the following locations: Aulnay-Sous-Bois, Bamako, 
Birmingham,  Bobigny,  Bordeaux  (2  centers),  Brest, 
Bristol,  Chambery,  Chateaulin,  Clermont-Ferrand 
(5 sites), Cournon, Dublin, Le Golfe Juan, Lesneven, 
London, Marseille, Palaiseau, Paris (2 sites), Sousse, 
  Tananarivo,  Thiers,  and  Toulon  (Transphyto  1994; 
Hoh  et  al  1996).54,55,70,72  Patients  were  given  either 
ganciclovir 0.15% or acyclovir 3% 5 times daily until 
healing of the ulcer and then 3 times daily for 1 week. 
The  clinical  study  results  showed  that  ganciclovir 
0.15% was as at least as effective as acyclovir 3% for 
the treatment of acute herpetic keratitis. The efficacy 
results for dendritic epithelial ulcers of the ITT and PP 
analyses were similar. In the ITT dendritic epithelial 
ulcer groups, the percent healed on day 14 were 88.7% 
in the ganciclovir 0.15% group and 91% in the acyclo-
vir 3% group, and in the PP group, the percent healed 
were 92.2% and 93.6% for ganciclovir and acyclovir 
groups respectively. The median time to healing was 
7 days for the ITT analysis for both treatment groups, 
and 6 days and 7 days for the PP analysis for the gan-
ciclovir 0.15% and acyclovir 3% groups, respectively. 
None of these results were statistically significant.
In  summary,  ganciclovir  0.15%  ophthalmic  gel 
showed a comparable efficacy to acyclovir 3% oph-
thalmic ointment in all four studies mentioned above. 
Moreover,  ganciclovir  0.15%  gel  was  associated 
with a lower relapse rate when compared to that of 
  acyclovir. There were no statistically significant dif-
ferences  between  healing  rates  of  ganciclovir  and 
acyclovir (83%–89% with ganciclovir and 71%–92% 
with acyclovir) Since study I reported the number of 
eyes treated, whereas studies II–IV reported the num-
ber of patients treated, and patient recruitment goals 
were not met, it was impossible to calculate the sta-
tistical significance between treatments. However, a 
pooled analysis of intent-to-treat patients in the three 
studies revealed a statistically significant difference 
in treatment success (ulcer resolution at end-point) 
between ganciclovir 0.15% (85%) and acyclovir 3% 
(71%) (P = 0.04).29,31,55
Acyclovir  resistance  has  been  a  concern  given 
the  widespread  use  of  acyclovir  for  treatment  and 
long-term  prophylaxis.  Since  acyclovir  and  ganci-
clovir are similar in structure, cross-resistance is a 
growing problem especially in immunocompromised 
patients.74 The prevalence of acyclovir-resistant HSV 
isolates is low in the immunocompetent population 
(0.1%–0.98%).75,76 In comparison, resistant isolates 
are  more  common  in  the  diverse  immunocompro-
mised patients (3.92%–14.3%).74–77Ganciclovir gel in acute herpetic keratitis
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In  a  study  of  173  immunocompetent  patients 
with HSV keratitis by Duan et al,78 11 (6.4%) had 
acyclovir-  resistant isolates. Ten of the 11 had   mutations 
in the viral thymidine kinase gene conferring the resis-
tant phenotype. Another study analyzed 40 HSV-1 iso-
lates from 35 patients in whom thirteen of the cases 
had keratitis and found that one isolate was resistant 
whereas three had reduced sensitivity.79 The principal 
mechanism of resistance to ganciclovir is the decreased 
ability to form the active triphosphate moiety. Muta-
tions  in  the  viral  DNA  polymerase  have  also  been 
reported to confer viral resistance to ganciclovir.47
patient preference
The patient preference and tolerability were studied 
in those four single-blinded randomized studies men-
tioned above. Because there was relatively few number 
of individuals in each trial, pooled data from all these 
trials were reviewed in FDA drug approval review. 
Local tolerability was found to be better in the recipi-
ents of ganciclovir ophthalmic gel 0.15%, than recip-
ients of acyclovir ointment 3%, when assessed by 
study investigator (79% vs. 44%; P , 0.001) and by 
the patient (75% vs. 44%; P , 0.001) in study 4. In 
study 2, these numbers were 82% vs. 19%; P , 0.001 
and 61% vs. 19%; P , 0.05, respectively.28,29,54,65,80 
The major advantage of ganciclovir over acyclovir is 
its aqueous formulation. This feature let the drug be 
tolerated better than acyclovir. It caused less sting-
ing and burning and most importantly less blurring of 
vision, improving tolerability significantly.
place in Therapy
The treatment and prophylaxis of herpetic keratitis 
is expensive.81 Approximately 17 million US dollars 
are spent annually to treat new and recurrent herpetic 
cases. While significant progress has been made in 
the treatment of ocular herpes infection during the 
last two decades, the toxicity of some antiviral agents 
still remains as a major problem. Epithelial keratitis 
is most often treated with topical and/or oral anti-
viral therapy. Idoxuridine, iododesoxycytidine, and 
vidarabine are very toxic and are no longer in use. 
  Trifluridine 1%, until recently, the only topical agent 
available in the United States, has very high toxic-
ity as well, while acyclovir and ganciclovir are less 
toxic agents, do to the higher selectivity. However, 
acyclovir ophthalmic ointment 3% is not commer-
cially  available  in  the  United  States.  Ganciclovir 
has been approved in the Unites States since 2009 
and is   indicated for epithelial dendritic ulcers only. 
  However, in Europe and other countries the indica-
tion for ganciclovir is not specified.
Currently, acyclovir 3% ophthalmic ointment and 
ganciclovir ophthalmic gel 0.15% are being used as 
a first line treatment for the treatment of acute epi-
thelial  herpetic  keratitis  outside  the  United  States. 
Ganciclovir 0.15% ophthalmic gel is recommended 
as one drop five times daily until corneal ulcer heals, 
followed by one drop three times daily for 7 days.43 
Although acyclovir ointment has an excellent sys-
temic safety profile, it suffers from two major draw-
backs: epithelial toxicity and poor patient tolerance 
due  to  blurring  and  stinging.  Randomized  clinical 
trials demonstrated that ganciclovir ophthalmic gel 
0.15%  caused  less  visual  disturbances  and  toxic-
ity among patients when compared to acyclovir 3% 
  ointment. The efficacy of ganciclovir was analyzed 
in a meta-analysis reported in Cochrane database.26 
There was no difference in terms of odds ratio in the 
efficacy against herpetic epithelial keratitis between 
acyclovir 3% and ganciclovir 0.15%.
Topical ganciclovir ophthalmic gel 0.15% has a 
good tolerance, prolonged corneal contact time, a sim-
ilar tonicity to tears, and a long and stable shelf life. Its 
pH is adjusted to a physiological level. It has a good 
penetration into the aqueous humor. It is as effective 
as acyclovir but at a much lower   concentration. Given 
these characteristics,   ganciclovir ophthalmic gel has 
a promising place in the treatment of acute epithelial 
herpetic keratitis (Table 3).   Long-term prophylaxis 
with ganciclovir in patients with recurrent herpetic 
keratitis has not been evaluated.   Recurrence of her-
petic keratitis in the corneal graft is a challenging 
Table 3. Benefits of ganciclovir ophthalmic gel.
Broad spectrum against herpes viridae
Selective efficacy on infected cells with virus
Aqueous humor penetration
Long shelf life
Physiologic pH
Prolonged corneal contact time
Good tolerability (No blurred vision, stinging, and burning)
No systemic side effectSahin and Hamrah
32  Ophthalmology and Eye Diseases 2012:4
the manuscript: AS, PH.   Contributed to the writing 
of the manuscript: AS, PH. Agree with manuscript 
results and conclusions: AS, PH. Jointly developed 
the structure and arguments for the paper: AS, PH. 
Made   critical revisions and approved final version: 
AS, PH. All authors reviewed and approved of the 
final manuscript.
competing Interests
None of the authors have financial disclosure.
Disclosures and ethics
As a requirement of publication author(s) have pro-
vided to the publisher signed confirmation of com-
pliance with legal and ethical obligations including 
but  not  limited  to  the  following:  authorship  and 
contributorship,  conflicts  of  interest,  privacy  and 
confidentiality and (where applicable) protection of 
human and animal research subjects. The authors 
have read and confirmed their agreement with the 
icmje  authorship  and  conflict  of  interest  criteria. 
The authors have also confirmed that this article is 
unique and not under consideration or published in 
any other publication, and that they have permission 
from rights holders to reproduce any copyrighted 
material. Any disclosures are made in this section. 
The external blind peer reviewers report no conflicts 
of interest. Provenance: the authors were invited to 
submit this paper.
References
1.  Holland  EJ,  Brilakis  HS,  Schwartz  GS.  Herpes  Simplex  Keratitis. 
In:   Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea: Elsevier Mosby, 
2005;1.
2.  Holland EJ, Schwartz GS. Classification of herpes simplex virus keratitis. 
Cornea. 1999;18(2):144–54.
3.  Stevens  JG,  Nesburn AB,  Cook  ML.  Latent  herpes  simplex  virus  from 
trigeminal ganglia of rabbits with recurrent eye infection. Nat New Biol. 
1972;235(59):216–7.
4.  Obara Y, Furuta Y, Takasu T, et al. Distribution of herpes simplex virus 
types 1 and 2 genomes in human spinal ganglia studied by PCR and in situ 
  hybridization. J Med Virol. 1997;52(2):136–42.
5. Dawson CR, Togni B. Herpes simplex eye infections: clinical manifes-
tations,  pathogenesis  and  management.  Surv  Ophthalmol.  1976;21(2):   
121–35.
6.  Pepose  J,  Keadle  T,  Morrison  L.  Ocular  herpes  simplex:  changing 
  epidemiology,  emerging  disease  patterns,  and  the  potential  of  vaccine 
  prevention and therapy. Am J Ophthalmol. 2006;141(3):547–77.
7.  Liesegang TJ. Herpes simplex virus epidemiology and ocular importance. 
Cornea. 2001;20(1):1–13.
8.  Liesegang TJ. A community study of ocular herpes simplex. Curr Eye Res. 
1991;10 Suppl:111–5.
9.  Liesegang  TJ.  Epidemiology  of  ocular  herpes  simplex.  Natural  history 
in  Rochester,  Minn,  1950  through  1982.  Arch  Ophthalmol.  1989;107(8): 
1160–5.
problem. The  failure rate is about 50%   following cor-
neal transplantation in patients with herpetic   keratitis. 
Low-dose  oral    acyclovir  is  effective  in    preventing 
recurrent  herpetic  keratitis.  However,  it  does  not 
appear to be cost-effective.81 Topical use of ganciclo-
vir in those patients may potentially prevent systemic 
side effects of oral antiviral therapy. Moreover the 
solid aqueous humor penetration of ganciclovir may 
be beneficial for the treatment and prophylaxis of her-
petic keratitis.   However, additional studies are needed 
to demonstrate the long-term safety and efficacy of 
ganciclovir in the treatment of herpetic keratitis.
conclusions
Herpetic keratitis is a major cause of blindness in 
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